These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31880795)

  • 1. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
    Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
    Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
    Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
    Fowke JH; Howard L; Andriole GL; Freedland SJ
    Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
    Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
    Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
    Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
    Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
    Chen H; Na R; Packiam VT; Conran CA; Jiang D; Tao S; Yu H; Lin X; Meng W; Zheng SL; Brendler CB; Helfand BT; Xu J
    Prostate; 2017 Aug; 77(11):1179-1186. PubMed ID: 28670847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial.
    Milonas D; Auskalnis S; Skulcius G; Gudinaviciene I; Jievaltas M; Joniau S
    World J Urol; 2017 May; 35(5):721-728. PubMed ID: 27644229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validity and utility of genetic risk scores in prostate cancer.
    Helfand BT; Kearns J; Conran C; Xu J
    Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
    Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
    Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).
    Thomas JA; Gerber L; Moreira DM; Hamilton RJ; BaƱez LL; Castro-Santamaria R; Andriole GL; Isaacs WB; Xu J; Freedland SJ
    J Intern Med; 2012 Jul; 272(1):85-92. PubMed ID: 22211699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dutasteride on the risk of prostate cancer.
    Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
    N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
    Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
    Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between family history of prostate cancer and positive biopsies in a Brazilian screening program.
    Muller RL; Faria EF; Carvalhal GF; Reis RB; Mauad EC; Carvalho AL; Freedland SJ
    World J Urol; 2013 Oct; 31(5):1273-8. PubMed ID: 22820620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of genetic risk score with family history for estimating prostate cancer risk.
    Helfand BT
    Asian J Androl; 2016; 18(4):515-9. PubMed ID: 27004541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
    Jamnagerwalla J; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
    J Urol; 2016 Sep; 196(3):715-20. PubMed ID: 27060053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
    Kader AK; Sun J; Reck BH; Newcombe PJ; Kim ST; Hsu FC; D'Agostino RB; Tao S; Zhang Z; Turner AR; Platek GT; Spraggs CF; Whittaker JC; Lane BR; Isaacs WB; Meyers DA; Bleecker ER; Torti FM; Trent JM; McConnell JD; Zheng SL; Condreay LD; Rittmaster RS; Xu J
    Eur Urol; 2012 Dec; 62(6):953-61. PubMed ID: 22652152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
    Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
    J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.